Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 10
Submit an article Journal homepage
441
Views
131
CrossRef citations to date
0
Altmetric
Review

TRAIL in cancer therapy: present and future challenges

Delphine Mérino INSERM, U866, Dijon, F-21079, France; Univ. Bourgogne, Dijon, F-21079, France [email protected]
,
Najoua Lalaoui INSERM, U866, Dijon, F-21079, France; Univ. Bourgogne, Dijon, F-21079, France [email protected]
,
Alexandre Morizot INSERM, U866, Dijon, F-21079, France; Univ. Bourgogne, Dijon, F-21079, France [email protected]
,
Eric Solary INSERM, U866, Dijon, F-21079, France; Univ. Bourgogne, Dijon, F-21079, France [email protected]
, MD PhD &
Olivier Micheau INSERM, U866, Dijon, F-21079, France; Univ. Bourgogne, Dijon, F-21079, France [email protected]
Pages 1299-1314 | Published online: 02 Oct 2007

Bibliography

  • PITTI RM, MARSTERS SA, RUPPERT S et al.: Induction of apoptosis by Apo-2 ligand, a new member of the TNF cytokine family. J. Biol. Chem. (1996) 271(22):12687-12690.
  • WILEY SR, SCHOOLEY K, SMOLAK PJ et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 3(6):673-682.
  • PAN G, O'ROURKE K, CHINNAIYAN AM et al.: The receptor for the cytotoxic ligand TRAIL. Science (1997) 276(5309):111-113.
  • CHAUDHARY PM, EBY M, JASMIN A et al.: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity (1997) 7(6):821-830.
  • WALCZAK H, DEGLI-ESPOSTI MA, JOHNSON RS et al.: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. (1997) 16(17):5386-5397.
  • DEGLI-ESPOSTI MA, SMOLAK PJ, WALCZAK H et al.: Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. (1997) 186(7):1165-1170.
  • PAN G, NI J, WEI YF et al.: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 277(5327):815-818.
  • DEGLI-ESPOSTI MA, DOUGALL WC, SMOLAK PJ et al.: The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 7(6):813-820.
  • VARFOLOMEEV E, MAECKER H, SHARP D et al.: Molecular determinants of kinase pathway activation by apo2 ligand/TNF related apoptosis-inducing ligand. J. Biol. Chem. (2005) 280(49):40599-40608.
  • MICHEAU O, TSCHOPP J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell (2003) 114(2):181-190.
  • LIABAKK NB, ESPEVIK T: Monoclonal antibodies against TRAIL. Vitam. Horm. (2004) 67:65-79.
  • ZAMAI L, AHMAD M, BENNETT IM et al.: Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. (1998) 188(12):2375-2380.
  • KAYAGAKI N, YAMAGUCHI N, NAKAYAMA M et al.: Type I interferons (IFNs) regulate TNF-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. (1999) 189(9):1451-1460.
  • GRIFFITH TS, WILEY SR, KUBIN MZ et al.: Monocyte-mediated tumoricidal activity via the TNF-related cytokine, TRAIL. J. Exp. Med. (1999) 189(8):1343-1354.
  • KOGA Y, MATSUZAKI A, SUMINOE A, HATTORI H, HARA T: Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res. (2004) 64(3):1037-1043.
  • KAYAGAKI N, YAMAGUCHI N, NAKAYAMA M et al.: Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. (1999) 162(5):2639-2647.
  • FANGER NA, MALISZEWSKI CR, SCHOOLEY K, GRIFFITH TS: Human dendritic cells mediate cellular apoptosis via TNF-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. (1999) 190(8):1155-1164.
  • LIU S, YU Y, ZHANG M, WANG W, CAO X: The involvement of TNF-α-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-β-stimulated human dendritic cells to tumor cells. J. Immunol. (2001) 166(9):5407-5415.
  • YU Y, LIU S, WANG W et al.: Involvement of TNF-α-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccharide-stimulated dendritic cells to activated T cells. Immunology (2002) 106(3):308-315.
  • KROLL TM, BOMMIASAMY H, BOISSY RE et al.: 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J. Invest. Dermatol. (2005) 124(4):798-806.
  • LU G, JANJIC BM, JANJIC J et al.: Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-α(1)β(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. (2002) 168(4):1831-1839.
  • SHI J, IKEDA K, FUJII N et al.: Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci. (2005) 96(2):127-133.
  • KAMOHARA H, MATSUYAMA W, SHIMOZATO O et al.: Regulation of TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology (2004) 111(2):186-194.
  • CRETNEY E, SHANKER A, YAGITA H, SMYTH MJ, SAYERS TJ: TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. (2006) 84(1):87-98.
  • CLARKE P, MEINTZER SM, GIBSON S et al.: Reovirus-induced apoptosis is mediated by TRAIL. J. Virol. (2000) 74(17):8135-8139.
  • HAN LH, SUN WS, MA CH et al.: Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J. Gastroenterol. (2002) 8(6):1077-1080.
  • WANDINGER KP, LUNEMANN JD, WENGERT O et al.: TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-β treatment in multiple sclerosis. Lancet (2003) 361(9374):2036-2043.
  • ROBERTSON NM, ZANGRILLI JG, STEPLEWSKI A et al.: Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival. J. Immunol. (2002) 169(10):5986-5996.
  • CRETNEY E, TAKEDA K, YAGITA H et al.: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. (2002) 168(3):1356-1361.
  • SMYTH MJ, TAKEDA K, HAYAKAWA Y et al.: Nature's TRAIL - on a path to cancer immunotherapy. Immunity (2003) 18(1):1-6.
  • ZERAFA N, WESTWOOD JA, CRETNEY E et al.: Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. (2005) 175(9):5586-5590.
  • SEDGER LM, GLACCUM MB, SCHUH JC et al.: Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. (2002) 32(8):2246-2254.
  • TAKEDA K, SMYTH MJ, CRETNEY E et al.: Critical role for TNF-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. (2002) 195(2):161-169.
  • HAYAKAWA Y, TAKEDA K, YAGITA H et al.: Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol. (2001) 31(6):1720-1727.
  • SEKI N, HAYAKAWA Y, BROOKS AD et al.: TNF-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. (2003) 63(1):207-213.
  • SMYTH MJ, CRETNEY E, TAKEDA K et al.: TNF-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. (2001) 193(6):661-670.
  • DIEHL GE, YUE HH, HSIEH K et al.: TRAIL-R as a negative regulator of innate immune cell responses. Immunity (2004) 21(6):877-889.
  • NESTEROV A, NIKRAD M, JOHNSON T, KRAFT AS: Oncogenic Ras sensitizes normal human cells to TNF-α-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. (2004) 64(11):3922-3927.
  • WANG Y, QUON KC, KNEE DA, NESTEROV A, KRAFT AS: RAS, MYC, and sensitivity to TNF-α-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. (2005) 65(4):1615-1616; author reply 1616-1617.
  • NIEMINEN AI, PARTANEN JI, HAU A, KLEFSTROM J: c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J. (2007) 26(4):1055-1067.
  • GROTZER MA, EGGERT A, ZUZAK TJ et al.: Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene (2000) 19(40):4604-4610.
  • KAGAWA S, HE C, GU J et al.: Antitumor activity and bystander effects of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. (2001) 61(8):3330-3338.
  • WAJANT H, PFIZENMAIER K, SCHEURICH P: TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis (2002) 7(5):449-459.
  • JIN Z, MCDONALD ER III, DICKER DT, EL-DEIRY WS: Deficient TNF-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. (2004) 279(34):35829-35839.
  • HORAK P, PILS D, HALLER G et al.: Contribution of epigenetic silencing of TNF-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol. Cancer Res. (2005) 3(6):335-343.
  • LEE SH, SHIN MS, KIM HS et al.: Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene (2001) 20(3):399-403.
  • NGUYEN T, ZHANG XD, HERSEY P: Relative resistance of fresh isolates of melanoma to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin. Cancer Res. (2001) 7(3 Suppl.):S966-S973.
  • FISHER MJ, VIRMANI AK, WU L et al.: Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. (2001) 7(6):1688-1697.
  • KIM K, FISHER MJ, XU SQ, EL-DEIRY WS: Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. (2000) 6(2):335-346.
  • PARK WS, LEE JH, SHIN MS et al.: Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology (2001) 121(5):1219-1225.
  • MCDONALD ER III, CHUI PC, MARTELLI PF, DICKER DT, EL-DEIRY WS: Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J. Biol. Chem. (2001) 276(18):14939-14945.
  • SPIERINGS DC, DE VRIES EG, VELLENGA E et al.: Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem. (2004) 52(6):821-831.
  • VAN NOESEL MM, VAN BEZOUW S, SALOMONS GS et al.: Tumor-specific down-regulation of the TNF-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. (2002) 62(7):2157-2161.
  • SHIVAPURKAR N, TOYOOKA S, TOYOOKA KO et al.: Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int. J. Cancer (2004) 109(5):786-792.
  • SHEIKH MS, HUANG Y, FERNANDEZ-SALAS EA et al.: The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene (1999) 18(28):4153-4159.
  • SANLIOGLU AD, KOKSAL IT, CIFTCIOGLU A et al.: Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J. Urol. (2007) 177(1):359-364.
  • AYDIN C, SANLIOGLU AD, KARACAY B et al.: Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred TNF-related apoptosis-inducing ligand resistance in lung cancer cells. Hum. Gene Ther. (2007) 18(1):39-50.
  • RICCIONI R, PASQUINI L, MARIANI G et al.: TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica (2005) 90(5):612-624.
  • GRIFFITH TS, CHIN WA, JACKSON GC, LYNCH DH, KUBIN MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. (1998) 161(6):2833-2840.
  • HAO C, BEGUINOT F, CONDORELLI G et al.: Induction and intracellular regulation of TNF-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. (2001) 61(3):1162-1170.
  • MITSIADES N, POULAKI V, MITSIADES C, TSOKOS M: Ewing's sarcoma family tumors are sensitive to TNF-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res. (2001) 61(6):2704-2712.
  • ZHANG XD, FRANCO A, MYERS K et al.: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. (1999) 59(11):2747-2753.
  • DANIELS RA, TURLEY H, KIMBERLEY FC et al.: Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. (2005) 15(6):430-438.
  • LINCZ LF, YEH TX, SPENCER A: TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia (2001) 15(10):1650-1657.
  • ZHANG XD, FRANCO AV, NGUYEN T, GRAY CP, HERSEY P: Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J. Immunol. (2000) 164(8):3961-3970.
  • MACFARLANE M, AHMAD M, SRINIVASULA SM et al.: Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. (1997) 272(41):25417-25420.
  • TRUNEH A, SHARMA S, SILVERMAN C et al.: Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. (2000) 275(30):23319-23325.
  • LEE HW, LEE SH, LEE HW et al.: Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem. Biophys. Res. Commun. (2005) 330(4):1205-1212.
  • SHERIDAN JP, MARSTERS SA, PITTI RM et al.: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 277(5327):818-821.
  • MERINO D, LALAOUI N, MORIZOT A et al.: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. (2006) 26(19):7046-7055.
  • MARSTERS SA, SHERIDAN JP, PITTI RM et al.: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. (1997) 7(12):1003-1006.
  • BERNARD D, QUATANNENS B, VANDENBUNDER B, ABBADIE C: Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J. Biol. Chem. (2001) 276(29):27322-27328.
  • ZHANG XD, NGUYEN T, THOMAS WD, SANDERS JE, HERSEY P: Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. (2000):193-199.
  • BOURALEXIS S, FINDLAY DM, ATKINS GJ et al.: Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br. J. Cancer (2003) 89(1):206-214.
  • SANLIOGLU AD, DIRICE E, AYDIN C et al.: Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer (2005) 5(1):54.
  • CLANCY L, MRUK K, ARCHER K et al.: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA (2005) 102(50):18099-18104.
  • FALSCHLEHNER C, EMMERICH CH, GERLACH B, WALCZAK H: TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. (2007) 39(7-8):1462-1475.
  • HU WH, JOHNSON H, SHU HB: TNF-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. (1999) 274(43):30603-30610.
  • CHENG J, HYLANDER BL, BAER MR, CHEN X, REPASKY EA: Multiple mechanisms underlie resistance of leukemia cells to Apo2 ligand/TRAIL. Mol. Cancer Ther. (2006) 5(7):1844-1853.
  • FULDA S, KUFER MU, MEYER E et al.: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 20(41):5865-5877.
  • HOPKINS-DONALDSON S, ZIEGLER A, KURTZ S et al.: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. (2003) 10(3):356-364.
  • MCDONALD ER III, EL-DEIRY WS: Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc. Natl. Acad. Sci. USA (2004) 101(16):6170-6175.
  • ROTH W, REED JC: FLIP protein and TRAIL-induced apoptosis. Vitam. Horm. (2004) 67:189-206.
  • LEBLANC H, LAWRENCE D, VARFOLOMEEV E et al.: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. (2002) 8(3):274-281.
  • FULDA S, MEYER E, DEBATIN KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene (2002) 21(15):2283-2294.
  • HERSEY P, ZHANG XD: Overcoming resistance of cancer cells to apoptosis. J. Cell Physiol. (2003) 196(1):9-18.
  • CHEN X, THAKKAR H, TYAN F et al.: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene (2001) 20(42):6073-6083.
  • BORTUL R, TAZZARI PL, CAPPELLINI A et al.: Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIP(L) up-regulation. Leukemia (2003) 17(2):379-389.
  • KOBAYASHI S, WERNEBURG NW, BRONK SF, KAUFMANN SH, GORES GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 128(7):2054-2065.
  • WHANG YE, YUAN XJ, LIU Y, MAJUMDER S, LEWIS TD: Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitam. Horm. (2004) 67:409-426.
  • MARTELLI AM, TAZZARI PL, TABELLINI G et al.: A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia (2003) 17(9):1794-1805.
  • PUDUVALLI VK, SAMPATH D, BRUNER JM et al.: TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis (2005) 10(1):233-243.
  • RYCHAHOU PG, MURILLO CA, EVERS BM: Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery (2005) 138(2):391-397.
  • OKA N, TANIMOTO S, TAUE R et al.: Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by TNF-related apoptosis-inducing ligand. Cancer Sci. (2006) 97(10):1093-1098.
  • JIN Z, EL-DEIRY WS: Distinct signaling pathways in TRAIL- versus TNF-induced apoptosis. Mol. Cell Biol. (2006) 26(21):8136-8148.
  • MARTINON F, HOLLER N, RICHARD C, TSCHOPP J: Activation of a pro-apoptotic amplification loop through inhibition of NF-κB-dependent survival signals by caspase-mediated inactivation of RIP. FEBS Lett. (2000) 468(2-3):134-136.
  • KIM YS, SCHWABE RF, QIAN T, LEMASTERS JJ, BRENNER DA: TRAIL-mediated apoptosis requires NF-κB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology (2002) 36(6):1498-1508.
  • EHRHARDT H, FULDA S, SCHMID I et al.: TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene (2003) 22(25):3842-3852.
  • SHETTY S, GLADDEN JB, HENSON ES et al.: TNF-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NF-κB activation in epithelial derived cell lines. Apoptosis. (2002) 7(5):413-420.
  • BRAEUER SJ, BUNEKER C, MOHR A, ZWACKA RM: Constitutively activated NF-κB, but not induced NF-κB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol. Cancer Res. (2006) 4(10):715-728.
  • WADA T, PENNINGER JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene (2004) 23(16):2838-2849.
  • TRAN SE, HOLMSTROM TH, AHONEN M, KAHARI VM, ERIKSSON JE: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. (2001) 276(19):16484-16490.
  • LEE TJ, LEE JT, PARK JW, KWON TK: Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem. Biophys. Res. Commun. (2006) 351(4):1024-1030.
  • BORGES J, PANDIELLA A, ESPARIS-OGANDO A: Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal. (2007) 19(7):1473-1487.
  • FRESE S, PIRNIA F, MIESCHER D et al.: PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene (2003) 22(35):5427-5435.
  • JIN Z, DICKER DT, EL-DEIRY WS: Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (2002) 1(1):82-89.
  • RETZER-LIDL M, SCHMID RM, SCHNEIDER G: Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int. J. Cancer (2007) 121(1):66-75.
  • KOBAYASHI S, LEE SH, MENG XW et al.: Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J. Biol. Chem. (2007) 282(25):18407-18417.
  • IVANOV VN, ZHOU H, HEI TK: Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res. (2007) 67(11):5397-5407.
  • RAY S, SHYAM S, FRAIZER GC, ALMASAN A: S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol. Cancer Ther. (2007) 6(4):1368-1378.
  • KELLEY SK, ASHKENAZI A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. (2004) 4(4):333-339.
  • WALCZAK H, MILLER RE, ARIAIL K et al.: Tumoricidal activity of TNF-related apoptosis-inducing ligand in vivo. Nat. Med. (1999) 5(2):157-163.
  • YOUNES A, KADIN ME: Emerging applications of the TNF family of ligands and receptors in cancer therapy. J. Clin. Oncol. (2003) 21(18):3526-3534.
  • DEBATIN KM, KRAMMER PH: Death receptors in chemotherapy and cancer. Oncogene (2004) 23(16):2950-2966.
  • ASHKENAZI A, PAI RC, FONG S et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. (1999) 104(2):155-162.
  • KELLEY SK, HARRIS LA, XIE D et al.: Preclinical studies to predict the disposition of Apo2L/TNF-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. (2001) 299(1):31-38.
  • LAWRENCE D, SHAHROKH Z, MARSTERS S et al.: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. (2001) 7(4):383-385.
  • NAKA T, SUGAMURA K, HYLANDER BL et al.: Effects of TNF-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. (2002) 62(20):5800-5806.
  • OIKONOMOU E, KOTHONIDIS K, ZOGRAFOS G et al.: Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br. J. Cancer (2007) 97(1):73-84.
  • MITSIADES CS, TREON SP, MITSIADES N et al.: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 98(3):795-804.
  • POLLACK IF, ERFF M, ASHKENAZI A: Direct stimulation of apoptotic signaling by soluble Apo2l/TNF-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res. (2001) 7(5):1362-1369.
  • HYLANDER BL, PITONIAK R, PENETRANTE RB et al.: The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J. Transl. Med. (2005) 3(1):22.
  • JO M, KIM TH, SEOL DW et al.: Apoptosis induced in normal human hepatocytes by TNF-related apoptosis-inducing ligand. Nat. Med. (2000) 6(5):564-567.
  • HAO C, SONG JH, HSI B et al.: TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. (2004) 64(23):8502-8506.
  • KOSCHNY R, HOLLAND H, SYKORA J et al.: Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for TNF-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res. (2007) 13(11):3403-3412.
  • OIKONOMOU E, KOTHONIDIS K, ZOGRAFOS G et al.: Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br. J. Cancer (2007) 97(1):73-84.
  • BAADER E, TOLOCZKO A, FUCHS U et al.: TNF-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. (2005) 65(17):7888-7895.
  • TRAUZOLD A, SIEGMUND D, SCHNIEWIND B et al.: TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene (2006) 25(56):7434-7439.
  • THAI LE M, LABRINIDIS A, HAY S et al.: Apo2l/TNF-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res. (2006) 66(10):5363-5370.
  • VAN DER SLOOT AM, TUR V, SZEGEZDI E et al.: Designed TNF-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. USA (2006) 103(23):8634-8639.
  • SHIN JN, PARK SY, CHA JH et al.: Generation of a novel proform of TNF-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases. Exp. Cell Res. (2006) 312(19):3892-3898.
  • WENGER T, MATTERN J, HAAS TL et al.: Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther. (2006) 14(3):316-326.
  • KIM KU, SEO SY, HEO KY et al.: Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells. J. Korean Med. Sci. (2005) 20(6):1046-1052.
  • YOO J, CHOI S, HWANG KS et al.: Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. J. Gene Med. (2006) 8(2):163-174.
  • MOHR A, HENDERSON G, DUDUS L et al.: AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther. (2004) 11(6):534-543.
  • SHAH K, TUNG CH, BREAKEFIELD XO, WEISSLEDER R: In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol. Ther. (2005) 11(6):926-931.
  • SOVA P, REN XW, NI S et al.: A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. (2004) 9(4):496-509.
  • SONG K, BENHAGA N, ANDERSON RL, KHOSRAVI-FAR R: Transduction of TNF-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res. (2006) 66(12):6304-6311.
  • WENGER T, MATTERN J, HAAS TL et al.: Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther. (2007) 14(3):316-326.
  • MATSUBARA H, MIZUTANI Y, HONGO F et al.: Gene therapy with TRAIL against renal cell carcinoma. Mol. Cancer Ther. (2006) 5(9):2165-2171.
  • KASMAN L, LU P, VOELKEL-JOHNSON C: The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. (2006) 14(3):327-334.
  • PAN Q, LIU B, LIU J et al.: Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol. Cell. Biochem. (2007).
  • ISHII M, IWAI M, HARADA Y et al.: Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver. Cancer Lett. (2007) 245(1-2):134-143.
  • KEANE MM, ETTENBERG SA, NAU MM, RUSSELL EK, LIPKOWITZ S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. (1999) 59(3):734-741.
  • LACOUR S, MICHEAU O, HAMMANN A et al.: Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene (2003) 22(12):1807-1816.
  • SINGH TR, SHANKAR S, CHEN X, ASIM M, SRIVASTAVA RK: Synergistic interactions of chemotherapeutic drugs and TNF-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. (2003) 63(17):5390-5400.
  • BUCHSBAUM DJ, ZHOU T, LOBUGLIO AF: TRAIL receptor-targeted therapy. Future Oncol. (2006) 2(4):493-508.
  • GLINIAK B, LE T: TNF-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. (1999) 59(24):6153-6158.
  • MICHEAU O: Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin. Ther. Targets (2003) 7(4):559-573.
  • CHINNAIYAN AM, PRASAD U, SHANKAR S et al.: Combined effect of TNF-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA (2000) 97(4):1754-1759.
  • CIUSANI E, CROCI D, GELATI M et al.: In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J. Neurooncol. (2005) 71(1):19-25.
  • GONG B, ALMASAN A: Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. (2000) 60(20):5754-5760.
  • MARINI P, SCHMID A, JENDROSSEK V et al.: Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 5:5.
  • WISSINK EH, VERBRUGGE I, VINK SR et al.: TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother. Oncol. (2006) 80(2):214-222.
  • SHANKAR S, SINGH TR, SRIVASTAVA RK: Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms. Prostate (2004) 61(1):35-49.
  • FINNBERG N, GRUBER JJ, FEI P et al.: DR5 knockout mice are compromised in radiation-induced apoptosis. Mol. Cell Biol. (2005) 25(5):2000-2013.
  • GANTEN TM, KOSCHNY R, SYKORA J et al.: Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res. (2006) 12(8):2640-2646.
  • MEURETTE O, FONTAINE A, REBILLARD A et al.: Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann. NY Acad. Sci. (2006) 1090:209-216.
  • KOSCHNY R, WALCZAK H, GANTEN TM: The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med. (2007).
  • GEORGAKIS GV, LI Y, HUMPHREYS R et al.: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br. J. Haematol. (2005) 130(4):501-510.
  • MOTOKI K, MORI E, MATSUMOTO A et al.: Enhanced apoptosis and tumor regression induced by a direct agonist antibody to TNF-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res. (2005) 11(8):3126-3135.
  • PUKAC L, KANAKARAJ P, HUMPHREYS R et al.: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer (2005) 92(8):1430-1441.
  • VOELKEL-JOHNSON C: An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol. Ther. (2003) 2(3):283-290.
  • GONG J, YANG D, KOHANIM S et al.: Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol. Cancer Ther. (2006) 5(12):2991-3000.
  • MARINI P, DENZINGER S, SCHILLER D et al.: Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene (2006) 25(37):5145-5154.
  • NAWROCKI ST, CAREW JS, DOUGLAS L et al.: Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res. (2007) 67(14):6987-6994.
  • TAKEDA K, YAMAGUCHI N, AKIBA H et al.: Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. (2004) 199(4):437-448.
  • ZHANG L, ZHANG X, BARRISFORD GW, OLUMI AF: Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett. (2007) 251:146-147.
  • KOORNSTRA JJ, KLEIBEUKER JH, VAN GEELEN CM et al.: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J. Pathol. (2003) 200(3):327-335.
  • OZAWA F, FRIESS H, KLEEFF J et al.: Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. (2001) 163(1):71-81.
  • HOTTE SJ, HIRTE HW, CHEN EX et al.: HGS-ETR1, a fully human monoclonal antibody to the TNF-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a Phase I trial. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23(16S):3052.
  • PACEY S, PLUMMER RE, ATTARD G et al.: Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. J. Clin. Oncol., ASCO Annual Meeting Proceedings (2005) 23(16S):3055.
  • YOUNES A, VOSE J, ZELENETZ AD et al.: Results of a Phase II trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) (ETR1-HM01). 47th Annual Meeting of the American Society of Hematology, Atlanta, USA (10 – 13 December 2005).
  • KELLEY RF, TOTPAL K, LINDSTROM SH et al.: Receptor-selective mutants of apoptosis-inducing ligand 2/TNF-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. (2005) 280(3):2205-2212.
  • MACFARLANE M, INOUE S, KOHLHAAS SL et al.: Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. (2005) 12(7):773-782.
  • KURBANOV BM, FECKER LF, GEILEN CC, STERRY W, EBERLE J: Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4. Oncogene (2007) 26(23):3364-3377.
  • SUH WS, KIM YS, SCHIMMER AD et al.: Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia (2003) 17(11):2122-2129.
  • HYER ML, CROXTON R, KRAJEWSKA M et al.: Synthetic triterpenoids cooperate with TNF-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. (2005) 65(11):4799-4808.
  • SCHIMMER AD, THOMAS MP, HURREN R et al.: Identification of small molecules that sensitize resistant tumor cells to TNF-family death receptors. Cancer Res. (2006) 66(4):2367-2375.
  • PANNER A, PARSA AT, PIEPER RO: Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev. Anticancer Ther. (2006) 6(9):1313-1322.
  • INOUE T, SHIRAKI K, FUKE H et al.: Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs (2006) 17(3):261-268.
  • SAYERS TJ, MURPHY WJ: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother. (2006) 55(1):76-84.
  • KAUFMANN SH, STEENSMA DP: On the TRAIL of a new therapy for leukemia. Leukemia (2005) 19(12):2195-2202.
  • ZHANG XD, GILLESPIE SK, BORROW JM, HERSEY P: The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. (2003) 66(8):1537-1545.
  • VASILEVSKAYA IA, O'DWYER PJ: 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem. Pharmacol. (2005) 70(4):580-589.
  • MA Y, LAKSHMIKANTHAN V, LEWIS RW, KUMAR MV: Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol. Cancer Ther. (2006) 5(1):170-178.
  • WANG X, JU W, RENOUARD J et al.: 17-Allylamino-17-demethoxygeldanamycin synergistically potentiates TNF-induced lung cancer cell death by blocking the NF-κB pathway. Cancer Res. (2006) 66(2):1089-1095.
  • ALLADINA SJ, SONG JH, DAVIDGE ST, HAO C, EASTON AS: TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J. Vasc. Res. (2005) 42(4):337-347.
  • FULDA S, DEBATIN KM: 5-Aza-2′-deoxycytidine and IFN-γ cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene (2006) 25(37):5125-5133.
  • ERAMO A, PALLINI R, LOTTI F et al.: Inhibition of DNA methylation sensitizes glioblastoma for TNF-related apoptosis-inducing ligand-mediated destruction. Cancer Res. (2005) 65(24):11469-11477.
  • RAVI R, BEDI A: Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res. (2002) 62(15):4180-4185.
  • MERCHANT MS, YANG X, MELCHIONDA F et al.: Interferon-γ enhances the effectiveness of TNF-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res. (2004) 64(22):8349-8356.
  • PAPAGEORGIOU A, LASHINGER L, MILLIKAN R et al.: Role of TNF-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. (2004) 64(24):8973-8979.
  • FULDA S, DEBATIN KM: Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene (2004) 23(40):6702-6711.
  • SHIRAISHI T, YOSHIDA T, NAKATA S et al.: Tunicamycin enhances TNF-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. (2005) 65(14):6364-6370.
  • LU M, KWAN T, YU C et al.: Peroxisome proliferator-activated receptor γ agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J. Biol. Chem. (2005) 280(8):6742-6751.
  • ALTUCCI L, GRONEMEYER H: Retinoids and TRAIL: two cooperating actors to fight against cancer. Vitam. Horm. (2004) 67:319-345.
  • IZERADJENE K, DOUGLAS L, TILLMAN DM, DELANEY AB, HOUGHTON JA: Reactive oxygen species regulate caspase activation in TNF-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. (2005) 65(16):7436-7445.
  • OLTERSDORF T, ELMORE SW, SHOEMAKER AR et al.: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 435(7042):677-681.
  • YEOW WS, BARAS A, CHUA A et al.: Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. J. Thorac. Cardiovasc. Surg. (2006) 132(6):1356-1362.
  • FULDA S, WICK W, WELLER M, DEBATIN KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. (2002) 8(8):808-815.
  • LI L, THOMAS RM, SUZUKI H et al.: A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science (2004) 305(5689):1471-1474.
  • PETRUCCI E, PASQUINI L, PETRONELLI A et al.: A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol. Oncol. (2007) 105(2):481-492.
  • REN X, XU Z, MYERS JN, WU X: Bypass NF-κB-mediated survival pathways by TRAIL and Smac. Cancer Biol. Ther. (2007) [Epub ahead of print].
  • KARIKARI CA, ROY I, TRYGGESTAD E et al.: Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. (2007) 6(3):957-966.
  • DI PAOLO NC, TUVE S, NI S et al.: Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res. (2006) 66(2):960-969.
  • UNO T, TAKEDA K, KOJIMA Y et al.: Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. (2006) 12(6):693-698.
  • LIANG X, LIU Y, ZHANG Q et al.: Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J. Immunol. (2007) 178(1):503-510.
  • MUNDT B, WIRTH T, ZENDER L et al.: TNF related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut (2005) 54(11):1590-1596.
  • HIGUCHI H, BRONK SF, TANIAI M, CANBAY A, GORES GJ: Cholestasis increases TNF-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J. Pharm. Exp. Ther. (2002) 303(2):461-467.
  • ANEL A, BOSQUE A, NAVAL J et al.: Apo2L/TRAIL and immune regulation. Front. Biosci. (2007) 12:2074-2084.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.